Neurogene Inc.: BAKER BROS. ADVISORS LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Baker Bros. Advisors LP amended its Schedule 13G filing for Neurogene Inc., disclosing a change in its beneficial ownership stake in the company. The amendment was filed with the SEC under accession number 0001104659-26-128384. The filing signals a shift in the position of one of the biotechnology sector's most prominent specialist institutional investors in the clinical-stage gene therapy developer. Investors will watch for further 13G or 13D filings to gauge whether Baker Bros. is building or trimming its stake, and for any accompanying changes in Neurogene's share price or trading volume.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Neurogene Inc., Baker Bros. Advisors LP